LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: The Impact of High-Frequency Chest-Wall Compression on Mechanical Ventilation Delivery and Flow Bias.

    Ntoumenopoulos, George / Jones, Alison / Koutoumanou, Eirini / Shannon, Harriet

    Respiratory care

    2023  

    Abstract: Background: It is unclear if high-frequency chest-wall compression (HFCWC) has a role to assist with secretion clearance in patients on mechanical ventilation. The effect of HFCWC on the delivery of mechanical ventilation is unknown. This study ... ...

    Abstract Background: It is unclear if high-frequency chest-wall compression (HFCWC) has a role to assist with secretion clearance in patients on mechanical ventilation. The effect of HFCWC on the delivery of mechanical ventilation is unknown. This study describes the effect of HFCWC on mechanical ventilation delivery and flow bias in an orally intubated and mechanically ventilated bench model.
    Methods: An orally intubated mannequin was mechanically ventilated in 5 commonly used modes of ventilation at settings that reflect current practice. HFCWC was applied via a randomized combination of oscillation frequencies and pressure settings. Mechanical ventilator flow, flow bias, and breathing frequency were measured before and during the application of HFCWC.
    Results: HFCWC led to 3- to 7-fold increases in ventilator-delivered breathing frequency during synchronized intermittent mandatory ventilation, bi-level (with pressure support), bi-level-assist, and pressure-regulated volume control modes of ventilation. Only in the bi-level mode without pressure support was the ventilator breathing frequency unaffected by HFCWC. During HFCWC, peak inspiratory flow to peak expiratory flow ratios toward an expiratory flow bias, particularly at higher HFCWC pressures, only in pressure-regulated volume control and synchronized intermittent mandatory ventilation modes were peak inspiratory flow to peak expiratory flow ratios of <0.9 generated that would facilitate secretion clearance.
    Conclusions: HFCWC led to 3- to 7-fold increases in ventilator breathing frequency delivered by mechanical ventilation except in the bi-level mode. The bi-level mode may be the optimal mode to use HFCWC to minimize disruption to the delivered ventilator breathing frequency. The peak inspiratory flow to peak expiratory flow ratios < 0.9, the optimal flow bias for secretion clearance, was only achieved in the pressure-regulated volume control and synchronized intermittent mandatory ventilation modes. However, the findings in this bench model with a fixed low compliance may not be generalizable to the patient in the ICU, and we recommend further investigation into the effects of HFCWC in the patient in the ICU.
    Language English
    Publishing date 2023-08-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603252-7
    ISSN 1943-3654 ; 0098-9142 ; 0020-1324
    ISSN (online) 1943-3654
    ISSN 0098-9142 ; 0020-1324
    DOI 10.4187/respcare.10932
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The effect of ciprofloxacin prophylaxis during haematopoietic cell transplantation on infection episodes, exposure to treatment antimicrobials and antimicrobial resistance: a single-centre retrospective cohort study.

    Baltas, Ioannis / Kavallieros, Konstantinos / Konstantinou, Giannis / Koutoumanou, Eirini / Gibani, Malick M / Gilchrist, Mark / Davies, Frances / Pavlu, Jiri

    JAC-antimicrobial resistance

    2024  Volume 6, Issue 1, Page(s) dlae010

    Abstract: Objectives: Fluroquinolone prophylaxis during haematopoietic cell transplantation (HCT) remains contentious. We aimed to determine its effectiveness and association with exposure to treatment antimicrobials and antimicrobial resistance.: Methods: All ...

    Abstract Objectives: Fluroquinolone prophylaxis during haematopoietic cell transplantation (HCT) remains contentious. We aimed to determine its effectiveness and association with exposure to treatment antimicrobials and antimicrobial resistance.
    Methods: All admission episodes for HCT (
    Results: Allo-HCT was performed for 43.3% (173/400) of patients, auto-HCT for 56.7% (227/400). Allo-HCT was associated with an average of 1.01 fewer infection episodes per 100 admission days (95% CI 0.62-1.40,
    Conclusions: Ciprofloxacin prophylaxis in allo-HCT was associated with fewer infection episodes and reduced exposure to treatment antimicrobials. Mortality in auto-HCT remained low. A significant burden of antimicrobial resistance was detected in allo-HCT recipients.
    Language English
    Publishing date 2024-02-01
    Publishing country England
    Document type Journal Article
    ISSN 2632-1823
    ISSN (online) 2632-1823
    DOI 10.1093/jacamr/dlae010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Long-term outcome and risk factors for late mortality in Gram-negative bacteraemia: a retrospective cohort study.

    Baltas, Ioannis / Stockdale, Thomas / Tausan, Matija / Kashif, Areeba / Anwar, Javeria / Anvar, Junaid / Koutoumanou, Eirini / Sidebottom, David / Garcia-Arias, Veronica / Wright, Melanie / Democratis, Jane

    Journal of global antimicrobial resistance

    2021  Volume 25, Page(s) 187–192

    Abstract: Objectives: The long-term outcomes of patients following Gram-negative bacteraemia (GNB) are poorly understood. Here we describe a cohort of patients with GNB over a 2-year period and determine factors associated with late mortality (death between Days ... ...

    Abstract Objectives: The long-term outcomes of patients following Gram-negative bacteraemia (GNB) are poorly understood. Here we describe a cohort of patients with GNB over a 2-year period and determine factors associated with late mortality (death between Days 31 and 365 after detection of bacteraemia).
    Methods: This was a single-centre, retrospective, observational cohort study of 789 patients with confirmed Escherichia coli, Klebsiella spp. or Pseudomonas aeruginosa bacteraemia with a follow-up of 1 year. Multivariable survival analysis was used to determine risk factors for late mortality in patients who survived the initial 30-day period of infection.
    Results: Overall, 1-year all-cause mortality was 36.2%, with 18.1% of patients dying within 30 days and 18.1% of patients suffering late mortality. An adverse antimicrobial resistance profile [hazard ratio (HR) = 1.095 per any additional antimicrobial category, 95% confidence interval (CI) 1.018-1.178; P = 0.014] and infection with P. aeruginosa (HR = 2.08, 95% CI 1.11-3.88; P = 0.022) were independent predictors of late mortality. Other significant factors included Charlson comorbidity index and length of hospitalisation after the index blood culture.
    Conclusion: Patients with GNB have a poor long-term prognosis. Risk factors for greater mortality at 1 year include co-morbidity, length of hospitalisation, and infecting organism and its resistance profile.
    MeSH term(s) Bacteremia ; Cohort Studies ; Gram-Negative Bacterial Infections ; Humans ; Retrospective Studies ; Risk Factors
    Language English
    Publishing date 2021-04-02
    Publishing country Netherlands
    Document type Journal Article ; Observational Study
    ZDB-ID 2710046-7
    ISSN 2213-7173 ; 2213-7165
    ISSN (online) 2213-7173
    ISSN 2213-7165
    DOI 10.1016/j.jgar.2021.03.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Impact of antibiotic timing on mortality from Gram-negative bacteraemia in an English district general hospital: the importance of getting it right every time.

    Baltas, Ioannis / Stockdale, Thomas / Tausan, Matija / Kashif, Areeba / Anwar, Javeria / Anvar, Junaid / Koutoumanou, Eirini / Sidebottom, David / Garcia-Arias, Veronica / Wright, Melanie / Democratis, Jane

    The Journal of antimicrobial chemotherapy

    2020  Volume 76, Issue 3, Page(s) 813–819

    Abstract: Objectives: There is limited evidence that empirical antimicrobials affect patient-oriented outcomes in Gram-negative bacteraemia. We aimed to establish the impact of effective antibiotics at four consecutive timepoints on 30 day all-cause mortality and ...

    Abstract Objectives: There is limited evidence that empirical antimicrobials affect patient-oriented outcomes in Gram-negative bacteraemia. We aimed to establish the impact of effective antibiotics at four consecutive timepoints on 30 day all-cause mortality and length of stay in hospital.
    Methods: We performed a multivariable survival analysis on 789 patients with Escherichia coli, Klebsiella spp. and Pseudomonas aeruginosa bacteraemias. Antibiotic choices at the time of the blood culture (BC), the time of medical clerking and 24 and 48 h post-BC were reviewed.
    Results: Patients that received ineffective empirical antibiotics at the time of the BC had higher risk of mortality before 30 days (HR = 1.68, 95% CI = 1.19-2.38, P = 0.004). Mortality was higher if an ineffective antimicrobial was continued by the clerking doctor (HR = 2.73, 95% CI = 1.58-4.73, P < 0.001) or at 24 h from the BC (HR = 1.83, 95% CI = 1.05-3.20, P = 0.033) when compared with patients who received effective therapy throughout. Hospital-onset infections, 'high inoculum' infections and elevated C-reactive protein, lactate and Charlson comorbidity index were independent predictors of mortality. Effective initial antibiotics did not statistically significantly reduce length of stay in hospital (-2.98 days, 95% CI = -6.08-0.11, P = 0.058). The primary reasons for incorrect treatment were in vitro antimicrobial resistance (48.6%), initial misdiagnosis of infection source (22.7%) and non-adherence to hospital guidelines (15.7%).
    Conclusions: Consecutive prescribing decisions affect mortality from Gram-negative bacteraemia.
    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Bacteremia/drug therapy ; Escherichia coli ; Escherichia coli Infections/drug therapy ; Gram-Negative Bacterial Infections/drug therapy ; Hospitals, General ; Humans ; Retrospective Studies ; Risk Factors
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2020-12-01
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 191709-2
    ISSN 1460-2091 ; 0305-7453
    ISSN (online) 1460-2091
    ISSN 0305-7453
    DOI 10.1093/jac/dkaa478
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing.

    Arulogun, Suzanne O / Brian, Duncan / Goradia, Harshita / Cooney, Aaron / Menne, Tobias / Koo, RayMun / O'Neill, Aideen T / Vos, Josephine M I / Pratt, Guy / Turner, Deborah / Marshall, Kirsty / Manos, Kate / Anderson, Claire / Gavriatopoulou, Maria / Kyriakou, Charalampia / Kersten, Marie J / Minnema, Monique C / Koutoumanou, Eirini / El-Sharkawi, Dima /
    Linton, Kim / Talaulikar, Dipti / McCarthy, Helen / Bishton, Mark / Follows, George / Wechalekar, Ashutosh / D'Sa, Shirley P

    American journal of hematology

    2023  Volume 98, Issue 5, Page(s) 750–759

    Abstract: Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well-established, and the impact of its use in different ... ...

    Abstract Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well-established, and the impact of its use in different treatment settings is not clear. We aimed to report response rates and survival outcomes following BR, and clarify the impact of depth of response and bendamustine dose on survival. A total of 250 WM patients treated with BR in the frontline or relapsed settings were included in this multicenter, retrospective cohort analysis. Rates of partial response (PR) or better differed significantly between the frontline and relapsed cohorts (91.4% vs 73.9%, respectively; p < 0.001). Depth of response impacted survival outcomes: two-year predicted PFS rates after achieving CR/VGPR vs PR were 96% versus 82%, respectively (p = 0.002). Total bendamustine dose was predictive of PFS: in the frontline setting, PFS was superior in the group receiving ≥1000 mg/m
    MeSH term(s) Humans ; Rituximab/therapeutic use ; Bendamustine Hydrochloride/therapeutic use ; Waldenstrom Macroglobulinemia/drug therapy ; Treatment Outcome ; Retrospective Studies ; Neoplasm Recurrence, Local/drug therapy ; Antineoplastic Combined Chemotherapy Protocols
    Chemical Substances Rituximab (4F4X42SYQ6) ; Bendamustine Hydrochloride (981Y8SX18M)
    Language English
    Publishing date 2023-03-20
    Publishing country United States
    Document type Multicenter Study ; Journal Article
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26895
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Exploring the views of infection consultants in England on a novel delinked funding model for antimicrobials: the SMASH study.

    Baltas, Ioannis / Gilchrist, Mark / Koutoumanou, Eirini / Gibani, Malick M / Meiring, James E / Otu, Akaninyene / Hettle, David / Thompson, Ameeka / Price, James R / Crepet, Anna / Atomode, Abolaji / Crocker-Buque, Timothy / Spinos, Dimitrios / Guyver, Hudson / Tausan, Matija / Somasunderam, Donald / Thoburn, Maxwell / Chan, Cathleen / Umpleby, Helen /
    Sharp, Bethany / Chivers, Callum / Vaghela, Devan Suresh / Shah, Ronak J / Foster, Jonathan / Hume, Amy / Smith, Christopher / Asif, Ammara / Mermerelis, Dimitrios / Reza, Mohammad Abbas / Haigh, Dominic A / Lamb, Thomas / Karatzia, Loucia / Bramley, Alexandra / Kadam, Nikhil / Kavallieros, Konstantinos / Garcia-Arias, Veronica / Democratis, Jane / Waddington, Claire S / Moore, Luke S P / Aiken, Alexander M

    JAC-antimicrobial resistance

    2023  Volume 5, Issue 4, Page(s) dlad091

    Abstract: Objectives: A novel 'subscription-type' funding model was launched in England in July 2022 for ceftazidime/avibactam and cefiderocol. We explored the views of infection consultants on important aspects of the delinked antimicrobial funding model.: ... ...

    Abstract Objectives: A novel 'subscription-type' funding model was launched in England in July 2022 for ceftazidime/avibactam and cefiderocol. We explored the views of infection consultants on important aspects of the delinked antimicrobial funding model.
    Methods: An online survey was sent to all infection consultants in NHS acute hospitals in England.
    Results: The response rate was 31.2% (235/753). Most consultants agreed the model is a welcome development (69.8%, 164/235), will improve treatment of drug-resistant infections (68.5%, 161/235) and will stimulate research and development of new antimicrobials (57.9%, 136/235). Consultants disagreed that the model would lead to reduced carbapenem use and reported increased use of cefiderocol post-implementation. The presence of an antimicrobial pharmacy team, requirement for preauthorization by infection specialists, antimicrobial stewardship ward rounds and education of infection specialists were considered the most effective antimicrobial stewardship interventions. Under the new model, 42.1% (99/235) of consultants would use these antimicrobials empirically, if risk factors for antimicrobial resistance were present (previous infection, colonization, treatment failure with carbapenems, ward outbreak, recent admission to a high-prevalence setting).Significantly higher insurance and diversity values were given to model antimicrobials compared with established treatments for carbapenem-resistant infections, while meropenem recorded the highest enablement value. Use of both 'subscription-type' model drugs for a wide range of infection sites was reported. Respondents prioritized ceftazidime/avibactam for infections by bacteria producing OXA-48 and KPC and cefiderocol for those producing MBLs and infections with
    Conclusions: The 'subscription-type' model was viewed favourably by infection consultants in England.
    Language English
    Publishing date 2023-08-01
    Publishing country England
    Document type Journal Article
    ISSN 2632-1823
    ISSN (online) 2632-1823
    DOI 10.1093/jacamr/dlad091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Clinical and microbiologic features guiding treatment recommendations for brain abscesses in children.

    Felsenstein, Susanna / Williams, Bhanu / Shingadia, Delane / Coxon, Lucy / Riordan, Andrew / Demetriades, Andreas K / Chandler, Christopher L / Bassi, Sanj / Koutoumanou, Eirini / Stapleton, Simon / Sharland, Mike / Bryant, Penelope A

    The Pediatric infectious disease journal

    2013  Volume 32, Issue 2, Page(s) 129–135

    Abstract: Background: There are no guidelines for the management of brain abscesses in children, and there is a paucity of recent data describing clinical and microbiologic features. We aimed to identify factors affecting outcome to inform antibiotic ... ...

    Abstract Background: There are no guidelines for the management of brain abscesses in children, and there is a paucity of recent data describing clinical and microbiologic features. We aimed to identify factors affecting outcome to inform antibiotic recommendations.
    Methods: From 1999 to 2009, 118 children presented with brain abscesses to 4 neurosurgical centers in the United Kingdom. Clinical, microbiologic and treatment data were collected.
    Results: The commonest preceding infection was sinusitis, with 59% of all children receiving antibiotics before diagnosis. Nonspecific symptoms were common, with only 13% having the triad of fever, headache and focal neurological deficit. Time between symptom onset and diagnosis varied widely (median, 10 days; range, 0-44). Magnetic resonance imaging was more frequently diagnostic than computed tomography. The most frequent organisms were Streptococcus milleri (38%), except after penetrating head injury or neurosurgery, for which Staphylococcus aureus was most common. The commonest empiric antibiotics were ceftriaxone/cefotaxime and metronidazole, which offered effective antimicrobial therapy in up to 83% of cases. Metronidazole added benefit in a maximum of 7% of cases, with ceftriaxone/cefotaxime alone sufficient in at least 76% and in all cases with cyanotic congenital heart disease or meningitis. A carbapenem would have been effective in 90%. The case fatality rate was 6% (33% in the immunocompromised). Long-term neurological sequelae affected 35%. Age younger than 5 years and a Glasgow Coma Scale score ≤8 were associated with poor outcome at 6 months.
    Conclusions: We recommend ceftriaxone/cefotaxime and metronidazole as empiric treatment, although metronidazole may be unnecessary in many cases, with antistaphylococcal cover in cases of head trauma. Meropenem potentially would be a better choice in the immunocompromised. A prospective study of intravenous and oral treatment guided by clinical improvement is required beause 1-2 weeks of intravenous antibiotics during a total of 6 weeks may be sufficient in children.
    MeSH term(s) Adolescent ; Anti-Bacterial Agents/administration & dosage ; Brain Abscess/epidemiology ; Brain Abscess/microbiology ; Brain Abscess/therapy ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Practice Guidelines as Topic ; Retrospective Studies ; Risk Factors ; Staphylococcal Infections/epidemiology ; Staphylococcal Infections/microbiology ; Staphylococcal Infections/therapy ; Staphylococcus aureus/isolation & purification ; Streptococcal Infections/epidemiology ; Streptococcal Infections/microbiology ; Streptococcal Infections/therapy ; Streptococcus milleri Group/isolation & purification ; Treatment Outcome ; United Kingdom/epidemiology
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2013-02
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 392481-6
    ISSN 1532-0987 ; 0891-3668
    ISSN (online) 1532-0987
    ISSN 0891-3668
    DOI 10.1097/INF.0b013e3182748d6e
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top